Expression of Androgen Receptor Coregulators in Prostate Cancer

Total Page:16

File Type:pdf, Size:1020Kb

Expression of Androgen Receptor Coregulators in Prostate Cancer 1032 Vol. 10, 1032–1040, February 1, 2004 Clinical Cancer Research Expression of Androgen Receptor Coregulators in Prostate Cancer Marika J. Linja,1 Kati P. Porkka,1 Conclusions: These findings suggest that the decreased Zhikang Kang,3 Kimmo J. Savinainen,1 expression of PIAS1 and SRC1 could be involved in the progression of prostate cancer. In addition, gene amplifica- Olli A. Ja¨nne,3 Teuvo L. J. Tammela,2 4 3 tion of SRC1 in one of the xenografts implies that, in some Robert L. Vessella, Jorma J. Palvimo, and tumors, genetic alteration of SRC1 may provide a growth 1 Tapio Visakorpi advantage. 1Laboratory of Cancer Genetics, Institute of Medical Technology and 2Department of Urology, University of Tampere and Tampere University Hospital, Tampere, Finland; 3Institute of Biomedicine, INTRODUCTION 4 University of Helsinki, Helsinki, Finland; and Department of The critical role of androgens in the development of pros- Urology, University of Washington, Seattle, Washington tate cancer is indicated, for example, by the fact that prostate cancer does not develop in men castrated early in their life (1). ABSTRACT In addition, more that 50 years ago, Huggins and Hodges (2) Purpose: The androgen receptor (AR)-mediated signal- showed that hormonal therapy is an effective treatment for ing pathway seems to be essentially involved in the develop- prostate cancer. Subsequently, androgen withdrawal has become ment and progression of prostate cancer. In vitro studies the standard and is practically the only effective treatment for have shown that altered expression of AR coregulators may advanced prostate cancer. Although most prostate carcinomas significantly modify transcriptional activity of AR, suggest- are originally androgen dependent, they eventually become hor- ing that these coregulators could also contribute to the mone refractory during treatment (3). The mechanisms under- progression of prostate cancer. Here, our goal was to assess lying the transition from androgen dependence to androgen alterations in the expression of the AR coregulators in pros- independence are incompletely understood. tate cancer in vivo. Androgen action in target tissues, such as the prostate Experimental Design: The expression of 16 AR coacti- gland, is mediated by nuclear androgen receptor (AR), which vators and corepressors (SRC1, ␤-catenin, TIF2, PIAS1, functions as a transcription factor. Several findings have already PIASx, ARIP4, BRCA1, AIB1, AIB3, CBP, STAT1, NCoR1, indicated that AR is involved in the development and progres- AES, cyclin D1, p300, and ARA24) was measured in prostate sion of prostate cancer. First, it has been suggested that certain cancer cell lines, xenografts, and clinical prostate tumor AR polymorphisms are associated with the risk of prostate specimens by using real-time quantitative reverse transcrip- cancer (4, 5). Second, somatic mutations of the AR gene have tion-PCR. In addition, gene copy number of SRC1 was been found, especially in tumors treated with antiandrogens analyzed by fluorescence in situ hybridization. such as flutamide and bicalutamide (6–8). Third, about one- Results: Both AR-positive and AR-negative cell lines third of the hormone-refractory prostate carcinomas contain and xenografts expressed the coregulators. Most of the co- amplification of the AR gene, leading to transcriptional up- regulators studied were expressed at equal levels in benign regulation of the gene (9, 10). In addition, hormone-refractory prostatic hyperplasia and untreated and hormone-refrac- tumors express more AR than the untreated tumors, even without tory carcinomas. However, the expression of PIAS1 and the gene amplification (10). Fourth, other growth factor signal- and 0.017, respectively) ing pathways may activate AR, especially in the presence of 0.048 ؍ SRC1 was significantly (P lower in hormone-refractory prostate tumors than in un- only low levels of androgens (11, 12). Finally, recent cDNA treated prostate tumors. No overexpression of the coregula- microarray studies (13, 14) have demonstrated that many of the tors was found in the clinical material. Paradoxically, the androgen-regulated genes become up-regulated at the progres- SRC1 gene was found to be amplified and highly expressed sion of the disease during androgen withdrawal. in a LuCaP 70 prostate cancer xenograft. Activation of AR by androgens is a complex process. The apo-AR stays associated with chaperone proteins in the cyto- plasm. Ligand binding leads to conformational changes in the receptor and its translocation into the nucleus, where it binds to an androgen response element located in the regulatory regions Received 6/29/03; revised 11/4/03; accepted 11/4/03. of target genes (15). In addition to the AR itself, transcriptional Grant support: The Academy of Finland, the Cancer Society of Fin- regulation involves a large number of activating and repressing land, the Reino Lahtikari Foundation, the Medical Research Fund of proteins (16). In vitro studies have indicated that altered expres- Tampere University Hospital, Biocentrum Helsinki, the Sigrid Juse´lius Foundation, and the Finnish Life and Pension Insurance Companies. sion of some of these coregulators may modify transcriptional The costs of publication of this article were defrayed in part by the activity of AR (17–23). For example, overexpression of a p160 payment of page charges. This article must therefore be hereby marked family member, TIF2, in a cotransfection assay enhanced AR advertisement in accordance with 18 U.S.C. Section 1734 solely to transcriptional activity in the presence of several steroids, in- indicate this fact. Requests for reprints: Tapio Visakorpi, Institute of Medical Technol- cluding adrenal androgens, within physiological concentrations ogy, FIN-33014 University of Tampere, Tampere, Finland. Phone: (23). In addition, coregulators may modulate the effects of 358-3-215-7725; Fax: 358-3-215-8597; E-mail: [email protected]. antiandrogens. For instance, it has been reported that hydroxy- Downloaded from clincancerres.aacrjournals.org on September 29, 2021. © 2004 American Association for Cancer Research. Clinical Cancer Research 1033 flutamide paradoxically increases AR activity when CBP is standard curves, total RNA from LNCaP was used. After first- overexpressed (24). Therefore, changes in the expression of the strand cDNA synthesis, serial dilutions were made correspond- coregulators might be involved in the development and progres- ing to about 100, 20, 4, 0.8, 0.16, and 0.032 ng of total RNA. sion of prostate cancer (25). However, only a few studies on the Primer sequences used for PCR amplification of each gene are expression of the coregulators in prostate cancer have been given in Table 1. The primers were designed to correspond to published (22, 23, 26–28). different exons to avoid amplification of genomic DNA. We To evaluate the significance of alterations in the expression also checked carefully to ensure that the primers could not of AR coregulators in prostate cancer, we have measured the detect pseudogenes or retropseudogenes. The PCR reactions expression of 16 different putative AR coactivators and core- were performed in LightCycler apparatus (29) using an LC Fast pressors by using quantitative reverse transcription-PCR (RT- Start DNA SYBR Green I Kit (Roche Diagnostics, Mannheim, PCR). Clinical tumor samples, prostate cancer cell lines, and Germany). Thermocycling for each reaction was done in a final xenografts were analyzed. The expression data were also com- volume of 20 ␮l containing 2 ␮l of cDNA sample (or standard), ␮ ϫ bined with the data on the chromosomal alterations of the cell 4mM MgCl2, 0.5 M each primer, and 1 ready-to-use SYBR lines and xenografts, obtained previously by comparative Green I reaction mix including Taq DNA polymerase, reaction genomic hybridization, to identify putative amplifications of the buffer, and deoxynucleotide triphosphate mix. The cycling con- coregulator genes. Finally, the gene copy number of SRC1 was ditions were designed according to the manufacturer’s guide- studied by using fluorescence in situ hybridization (FISH). lines. The annealing temperatures are given in Table 1. The elongation time was calculated by dividing the size of the amplicon (Table 1) by 25. The fluorescence emitted by SYBR MATERIALS AND METHODS Green I was measured in every cycle at the end of the elongation Samples. The prostate cancer cell lines (LNCaP, PC-3, step or, to avoid any fluorescence from nonspecific products, at DU145, 22Rv1, and NCI-H660) were obtained from the Amer- higher temperatures (for PIASx, CBP, cyclin D1, p300, and ican Type Culture Collection (Manassas, VA) and cultured ARA24). After arithmetic background adjustment, the fit point under the recommended conditions. Freshly frozen samples of method was used to determine the crossing-point value as de- 10 prostate cancer xenografts (LuCaP 23.1, 23.8, 23.12, 35, 41, scribed previously (10). Fig. 1 illustrates an example of a 49, 58, 69, 70, and 73) were made available for the analyses by standard curve for PIAS1. For normalization of the expression one of the coauthors (R. L. V.). All xenografts, except LuCaP 49 levels, the expression of TATA box-binding protein (TBP) was and LuCaP 58, have been established from hormone-refractory measured as described previously (10). TBP was chosen as the human prostate carcinomas and propagated in intact male mice. reference gene because there are no known retropseudogenes for Freshly frozen prostate tumor specimens representing benign
Recommended publications
  • Signal Transducer and Activator of Transcription 5A/B in Prostate and Breast Cancers
    Endocrine-Related Cancer (2008) 15 367–390 REVIEW Signal transducer and activator of transcription 5A/B in prostate and breast cancers Shyh-Han Tan and Marja T Nevalainen Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, BLSB 309, Philadelphia, Pennsylvania 19107, USA (Correspondence should be addressed to M T Nevalainen; Email: [email protected]) Abstract Protein kinase signaling pathways, such as Janus kinase 2-Signal transducer and activator of transcription 5A/B (JAK2-STAT5A/B), are of significant interest in the search for new therapeutic strategies in both breast and prostate cancers. In prostate cancer, the components of the JAK2- STAT5A/B signaling pathway provide molecular targets for small-molecule inhibition of survival and growth signals of the cells. At the same time, new evidence suggests that the STAT5A/B signaling pathway is involved in the transition of organ-confined prostate cancer to hormone- refractory disease. This implies that the active JAK2-STAT5A/B signaling pathway potentially provides the means for pharmacological intervention of clinical prostate cancer progression. In addition, active STAT5A/B may serve as a prognostic marker for identification of those primary prostate cancers that are likely to progress to aggressive disease. In breast cancer, the role of STAT5A/B is more complex. STAT5A/B may have a dual role in the regulation of malignant mammary epithelium. Data accumulated from mouse models of breast cancer suggest that in early stages of breast cancer STAT5A/B may promote malignant transformation and enhance growth of the tumor. This is in contrast to established breast cancer, where STAT5A/B may mediate the critical cues for maintaining the differentiation of mammary epithelium.
    [Show full text]
  • Materials Express
    Materials Express 2158-5849/2020/10/1836/010 Copyright © 2020 by American Scientific Publishers All rights reserved. doi:10.1166/mex.2020.1822 Printed in the United States of America www.aspbs.com/mex Upregulation of signal transducer and activator of transcription 4 promotes osteoblast activity by activating AMP-activated protein kinase based on cationic liposome transfection Tao Jiang1,4,†, Qingzhen Chen1,2,†,MinShao2,∗, Zhen Shen3, Gang Wang3, Qinsheng Wang2, and Zhenming Zeng2 1The Third Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, PR China 2Department of Orthopedics, The Third Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510240, Guangdong, PR China 3The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, PR China 4 Department of Orthopedics, GuangdongIP: 192.168.39.151 Second Traditional On: Thu, Chinese 30 Sep Medicine 2021 19:20:15 Hospital, Guangzhou 510095, Guangdong, PR China Copyright: American Scientific Publishers Delivered by Ingenta Article ABSTRACT Activation of Protein Kinase AMP-Activated Catalytic Subunit Alpha (AMPK) is an important regulatory path- way for osteogenic differentiation. STAT4 acts as a transcriptional activity factor to regulate the transcription of many genes and is potentially a regulatory factor for AMPK transcription activity. To confirm the regulatory effect of STAT4 on AMPK and the effect of STAT4 on osteogenic differentiation, the promoter sequence of AMPK was analyzed via bioinformatics, the STAT4 overexpression vector was constructed and transfected into human osteoblast-like cells MG-63 by cationic liposome, fluorescence quantitative PCR (RT-qPCR) and western blotting technologies were used to detect the effect of STAT4 on the expression of AMPK.MTT and ALP activity assays were also used to verify the effect of STAT4 on the proliferation and maturation of osteoblasts by regulating AMPK expression.
    [Show full text]
  • Modulation of STAT Signaling by STAT-Interacting Proteins
    Oncogene (2000) 19, 2638 ± 2644 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc Modulation of STAT signaling by STAT-interacting proteins K Shuai*,1 1Departments of Medicine and Biological Chemistry, University of California, Los Angeles, California, CA 90095, USA STATs (signal transducer and activator of transcription) play important roles in numerous cellular processes Interaction with non-STAT transcription factors including immune responses, cell growth and dierentia- tion, cell survival and apoptosis, and oncogenesis. In Studies on the promoters of a number of IFN-a- contrast to many other cellular signaling cascades, the induced genes identi®ed a conserved DNA sequence STAT pathway is direct: STATs bind to receptors at the named ISRE (interferon-a stimulated response element) cell surface and translocate into the nucleus where they that mediates IFN-a response (Darnell, 1997; Darnell function as transcription factors to trigger gene activa- et al., 1994). Stat1 and Stat2, the ®rst known members tion. However, STATs do not act alone. A number of of the STAT family, were identi®ed in the transcription proteins are found to be associated with STATs. These complex ISGF-3 (interferon-stimulated gene factor 3) STAT-interacting proteins function to modulate STAT that binds to ISRE (Fu et al., 1990, 1992; Schindler et signaling at various steps and mediate the crosstalk of al., 1992). ISGF-3 consists of a Stat1:Stat2 heterodimer STATs with other cellular signaling pathways. This and a non-STAT protein named p48, a member of the article reviews the roles of STAT-interacting proteins in IRF (interferon regulated factor) family (Levy, 1997).
    [Show full text]
  • Interpretation of Cytokine Signaling Through the Transcription Factors STAT5A and STAT5B
    Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B Lothar Hennighausen1 and Gertraud W. Robinson Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA Transcription factors from the family of Signal Trans- the “wrong” STATs and thus acquire inappropriate cues. ducers and Activators of Transcription (STAT) are acti- We propose that mice with mutations in various com- vated by numerous cytokines. Two members of this fam- ponents of the JAK–STAT signaling pathway are living ily, STAT5A and STAT5B (collectively called STAT5), laboratories, which will provide insight into the versa- have gained prominence in that they are activated by a tility of signaling hardware and the adaptability of the wide variety of cytokines such as interleukins, erythro- software. poietin, growth hormone, and prolactin. Furthermore, constitutive STAT5 activation is observed in the major- ity of leukemias and many solid tumors. Inactivation Historical perspective studies in mice as well as human mutations have pro- In 1994, Bernd Groner and colleagues (Wakao et al. vided insight into many of STAT5’s functions. Disrup- 1994), then at the Friedrich Miescher Institute in Basel, tion of cytokine signaling through STAT5 results in a cloned a cDNA from lactating ovine mammary tissue variety of cell-specific effects, ranging from a defective that encoded a transcription factor promoting prolactin- immune system and impaired erythropoiesis, the com- induced transcription of milk protein genes in mammary plete absence of mammary development during preg- epithelium.
    [Show full text]
  • Stats: Transcriptional Control and Biological Impact
    REVIEWS STATS: TRANSCRIPTIONAL CONTROL AND BIOLOGICAL IMPACT David E. Levy* and J. E. Darnell Jr‡ Extracellular proteins bound to cell-surface receptors can change nuclear gene expression patterns in minutes, with far-reaching consequences for development, cell growth and homeostasis. The signal transducer and activator of transcription (STAT) proteins are among the most well studied of the latent cytoplasmic signal-dependent transcription-factor pathways. In addition to several roles in normal cell decisions, dysregulation of STAT function contributes to human disease, making the study of these proteins an important topic of current research. SIGNALLING SH2 DOMAIN This year marks the tenth anniversary of the recogni- and transphosphorylation on tyrosine residues, releasing (Src-homology-2 domain). A tion of the STAT proteins, named after their dual role as their intrinsic catalytic activity. Tyrosine phosphoryla- protein motif that recognizes signal transducers and activators of transcription1–4. tion by activated JAKs of cytokine-receptor cytoplasmic and binds tyrosine- These transcription factors are latent in the cytoplasm domains then provides binding sites for the Src-homol- phosphorylated sequences, and thereby has a key role in relaying until they are activated by extracellular signalling pro- ogy-2 (SH2) DOMAIN of the STAT proteins. The STAT pro- cascades of signal transduction. teins (mainly cytokines and growth factors, but also teins are then recruited to the JAKs, whereupon they are some peptides) that bind to specific cell-surface recep- phosphorylated on a single tyrosine residue (around tors. These extracellular-signalling proteins can activate residue 700 of their 750–850-amino-acid sequence). various tyrosine kinases in the cell that phosphorylate Although the interactions and consequences of STAT STAT proteins.
    [Show full text]
  • A STAT Protein Domain That Determines DNA Sequence Recognition Suggests a Novel DNA-Binding Domain
    Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain Curt M. Horvath, Zilong Wen, and James E. Darnell Jr. Laboratory of Molecular Cell Biology, The Rockefeller University, New York, New York 10021 Statl and Stat3 are two members of the ligand-activated transcription factor family that serve the dual functions of signal transducers and activators of transcription. Whereas the two proteins select very similar (not identical) optimum binding sites from random oligonucleotides, differences in their binding affinity were readily apparent with natural STAT-binding sites. To take advantage of these different affinities, chimeric Statl:Stat3 molecules were used to locate the amino acids that could discriminate a general binding site from a specific binding site. The amino acids between residues -400 and -500 of these -750-amino-acid-long proteins determine the DNA-binding site specificity. Mutations within this region result in Stat proteins that are activated normally by tyrosine phosphorylation and that dimerize but have greatly reduced DNA-binding affinities. [Key Words: STAT proteins; DNA binding; site selection] Received January 6, 1995; revised version accepted March 2, 1995. The STAT (signal transducers and activators if transcrip- Whereas oligonucleotides representing these selected se- tion) proteins have the dual purpose of, first, signal trans- quences exhibited slight binding preferences, the con- duction from ligand-activated receptor kinase com- sensus sites overlapped sufficiently to be recognized by plexes, followed by nuclear translocation and DNA bind- both factors. However, by screening different natural ing to activate transcription (Darnell et al.
    [Show full text]
  • Dihydrotestosterone Promotes Kidney Cancer Cell Proliferation by Activating the STAT5 Pathway Via Androgen and Glucocorticoid Receptors
    Journal of Cancer Research and Clinical Oncology (2019) 145:2293–2301 https://doi.org/10.1007/s00432-019-02993-1 ORIGINAL ARTICLE – CANCER RESEARCH Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors Sahyun Pak1 · Wansuk Kim2 · Yunlim Kim3,4 · Cheryn Song4 · Hanjong Ahn4 Received: 19 January 2019 / Accepted: 5 August 2019 / Published online: 10 August 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Purpose Androgen receptors (ARs) are expressed on a variety of cell types, and AR signaling plays an important role in tumor development and progression in several cancers. This in vitro study evaluated the efect of dihydrotestosterone (DHT) on the proliferation of renal cell carcinoma (RCC) cells in relation to AR status. Methods Steroid hormone receptor expression was evaluated using RT-PCR and Western blotting. The efect of DHT on cell proliferation and STAT5 phosphorylation was evaluated in RCC cell lines (Caki-2, A498, and SN12C) and primary RCC cells using cell viability assays and Western blotting. ARs and glucocorticoid receptors (GRs) were knocked down with small interfering RNAs before assessing changes in cell proliferation and STAT5 activation. Results DHT treatment promoted cell proliferation and increased STAT5 phosphorylation regardless of AR status. The AR antagonist bicalutamide reduced kidney cancer cell proliferation, regardless of AR status. AR and GR knockdown blocked STAT5 activation and reduced cell proliferation in all RCC cell lines. In patient-derived primary cells, DHT enhanced cell proliferation and this efect was diminished by treatment with the AR antagonists bicalutamide and enzalutamide and the GR antagonist mifepristone.
    [Show full text]
  • Analysis of Phosphorylated STAT Protein Signaling in Lymphocytes Using Flow Cytometry
    Application Note Cell Analysis Analysis of Phosphorylated STAT Protein Signaling in Lymphocytes Using Flow Cytometry Author Abstract Agilent Technologies, Inc. This application note examines the phosphorylation of signal transducer and activator of transcription (STAT) proteins in response to cytokine stimulation using a flow cytometry–based phosphoflow technique and the Agilent NovoCyte flow cytometer. The results demonstrate the efficacy of this approach for the rapid, quantitative, scalable, and multiparameter detection of phosphorylated protein in single cells. Introduction many cellular events including T and blotting, and mass spectrometry. B cell signaling, cell metabolism, cell Western blotting is the most commonly Protein phosphorylation is the growth, apoptosis, and other processes. used but has shortcomings; it is biological process of transferring semiquantitative, time-consuming, and Cytokines are a group of small a phosphate group to a substrate requires a large amount of starting secreted proteins important for protein, which primarily occurs on material. Also, cell separation may be immune cell-to-cell communication, tyrosine, serine, and threonine residues. required to isolate a pure population of a immune cell activation, differentiation, Protein phosphorylation can cause cells from a heterogeneous mixture. conformational changes, changes and migration towards the site of Analysis of phosphorylated proteins by in protein activity, or protein-protein inflammation/infection. Cytokines bind to flow cytometry or phosphoflow was interactions. This event can also initiate receptors on the cell surface and activate first described in the early 2000s. By a phosphorylation signaling cascade intracellular cascades, such as the Janus combining a phosphoflow methodology leading to a sequence of protein kinase (JAK)/STAT pathway. STATs are with cell surface antibody staining, rare phosphorylation events.
    [Show full text]
  • A Role for Stat-1 in Regulating Interleukin 10 Production Following Lps Challenge
    A ROLE FOR STAT-1 IN REGULATING INTERLEUKIN 10 PRODUCTION FOLLOWING LPS CHALLENGE DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University by Jeffrey Bryan VanDeusen, B.A. * * * * * The Ohio State University 2004 Dissertation Committee: Approved by Clay Marsh, MD Christoph Plass, PhD _______________________________ Michael A. Caligiuri, MD Denis Guttridge, PhD Adviser Department of Molecular Virology, Immunology, and Molecular Genetics ABSTRACT There have been substantial advances in understanding the events that regulate gene expression at the cellular and molecular level, however, there has been limited progress integrating this information to understand how biological systems function in vivo. Complementary DNA and protein microarray technologies in combination with sophisticated bioinformatics may eventually provide important insight into how biologic systems work in vivo. We hypothesized that assessments of such events in vivo would provide new insights into the immune response that could not be predicted or discovered ex vivo. Here, we describe the use of quantitative real time RT-PCR to serially quantify expression of a variety of pro- and anti-inflammatory cytokine genes in a number of individual tissues before, during, and after challenge with lipopolysaccharide (LPS). The data provide new insight into the heterogeneity of cytokine gene expression from organ to organ following infectious insult in vivo, as well as a greater understanding of cytokine regulation. For example, the anti- inflammatory cytokine interleukin-10 (IL-10) is thought to down-regulate the effects of the pro-inflammatory cytokine interferon gamma (IFN-γ) on monocyte activation following lipopolysaccharide (LPS) stimulation.
    [Show full text]
  • Type II Cgmp‑Dependent Protein Kinase Inhibits EGF‑Induced JAK/STAT Signaling in Gastric Cancer Cells
    MOLECULAR MEDICINE REPORTS 14: 1849-1856, 2016 Type II cGMP‑dependent protein kinase inhibits EGF‑induced JAK/STAT signaling in gastric cancer cells MIN WU, YAN WU, TING LAN, LU JIANG, HAI QIAN and YONGCHANG CHEN Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China Received June 20, 2015; Accepted June 7, 2016 DOI: 10.3892/mmr.2016.5452 Abstract. Previous research has demonstrated that type II Introduction cyclic guanosine monophosphate (cGMP)-dependent pro- tein kinase (PKG II) inhibited epidermal growth factor Janus kinase (JAK)-signal transducer and activator of tran- (EGF)-initiated signal transduction of MAPK-mediated, scription (STAT)-mediated signal transduction pathway is PI3K/Akt-mediated and PLCγ1-mediated pathways through important for regulating DNA transcription and the activi- blocking EGF-induced phosphorylation/activation of EGF re- ties of the cell cycle. This pathway has three main signaling ceptor (EGFR). As EGF/EGFR signaling also initiated signal components: Receptors, JAK, and STAT (1). Extracellular transduction of the Janus kinase (JAK)/signal transducer and signal molecules, including interferon, interleukin and growth activator of transcription (STAT)-mediated pathway, the pres- factors, can bind with their receptors and cause activation of ent study was performed to investigate whether PKG II exerts the kinase function of JAK through auto-phosphorylation. an inhibitory effect this pathway. AGS human gastric cancer Consequently, STAT binds to the phosphorylated receptor, cell line was infected with adenoviral constructs encoding the where it is phosphorylated by JAK. The phosphorylated STAT cDNA of PKG II (Ad-PKG II), to increase the expression of protein then binds to another phosphorylated STAT protein to PKG II, and treated with 8-pCPT-cGMP to activate the kinase.
    [Show full text]
  • STAT Proteins: Novel Molecular Targets for Cancer Drug Discovery
    Oncogene (2000) 19, 6613 ± 6626 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc STAT proteins: novel molecular targets for cancer drug discovery James Turkson1,2 and Richard Jove*1,2,3,4 1Molecular Oncology Program, H. Lee Mott Cancer Center and Research Institute, Tampa, Florida, USA; 2Department of Oncology, University of South Florida College of Medicine, Tampa, Florida, USA; 3Department of Biochemistry and Molecular Biology, University of South Florida College of Medicine, Tampa, Florida, USA; 4Department of Pathology, University of South Florida College of Medicine, Tampa, Florida, USA Signal Transducers and Activators of Transcription STAT monomers form dimers through reciprocal (STATs) are a family of cytoplasmic proteins with roles phosphotyrosine-SH2 interactions, translocate to the as signal messengers and transcription factors that nucleus, and bind to STAT-speci®c DNA-response participate in normal cellular responses to cytokines and elements of target genes to induce gene transcription. growth factors. Frequently, however, abnormal activity of To date, there are seven STAT family members certain STAT family members, particularly Stat3 and identi®ed in mammals, designated Stat1, Stat2, Stat3, Stat5, is associated with a wide variety of human Stat4, Stat5a, Stat5b and Stat6. STATs have diverse malignancies, including hematologic, breast, head and normal biological functions, which include roles in cell neck, and prostate cancers. Application of molecular dierentiation, proliferation, development, apoptosis, biology and pharmacology tools in disease-relevant models and in¯ammation (Akira, 2000; Bromberg et al., 1996; has con®rmed Stat3 as having a causal role in oncogenesis, Cressman et al., 1996; Fukada et al., 1996; Hirano et and provided validation of Stat3 as a target for cancer al., 2000; Kaplan et al., 1996a,b; Planas et al., 1997; drug discovery and therapeutic intervention.
    [Show full text]
  • Design Guidelines for Deploying Closed Loop Systems
    Graduate School ETD Form 9 (Revised 12/07) PURDUE UNIVERSITY GRADUATE SCHOOL Thesis/Dissertation Acceptance This is to certify that the thesis/dissertation prepared By Ivan Lupov Entitled "ACQUIRED STAT4 DEFICIENCY AS A CONSEQUENCE OF CANCER CHEMOTHERAPY" Master of Science For the degree of Is approved by the final examining committee: Hua-Chen Chang Chair Stephen Randall Michael Robertson To the best of my knowledge and as understood by the student in the Research Integrity and Copyright Disclaimer (Graduate School Form 20), this thesis/dissertation adheres to the provisions of Purdue University’s “Policy on Integrity in Research” and the use of copyrighted material. Approved by Major Professor(s): ____________________________________Hua-Chen Chang ____________________________________ Approved by: Simon Atkinson 4/15/2011 Head of the Graduate Program Date Graduate School Form 20 (Revised 9/10) PURDUE UNIVERSITY GRADUATE SCHOOL Research Integrity and Copyright Disclaimer Title of Thesis/Dissertation: "ACQUIRED STAT4 DEFICIENCY AS A CONSEQUENCE OF CANCER CHEMOTHERAPY" For the degree of MasterChoose ofyour Science degree I certify that in the preparation of this thesis, I have observed the provisions of Purdue University Executive Memorandum No. C-22, September 6, 1991, Policy on Integrity in Research.* Further, I certify that this work is free of plagiarism and all materials appearing in this thesis/dissertation have been properly quoted and attributed. I certify that all copyrighted material incorporated into this thesis/dissertation is in compliance with the United States’ copyright law and that I have received written permission from the copyright owners for my use of their work, which is beyond the scope of the law.
    [Show full text]